Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • Log out
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Articles

The Issues of Transport Multiplicity and Energetics Pertaining to Methotrexate Efflux in L1210 Cells Addressed by an Analysis of Cis and Trans Effects of Inhibitors

F. M. Sirotnak and D. F. O'Leary
F. M. Sirotnak
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. F. O'Leary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published March 1991
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Studies are described addressing the controversial issue of the multiplicity of efflux routes for [3H]MTX in L1210 cells. We examined efflux multiplicity under conditions that do and do not maintain cellular ATP at the physiological level. In ATP-replete cells, the results delineate a probenecid-, bromosulfophthalein-, and verapamil-inhibitable route that accounts for nearly 90% of [3H]MTX efflux. Efflux of [3H]MTX by this route is inhibited by bromosulfophthalein in the trans orientation only, inhibited by probenecid only when present simultaneously in the cis and trans orientation and inhibited by verapamil only in the cis orientation. The remaining efflux of this folate analogue in ATP-replete cells appears to be mediated by the one-carbon, reduced folate system (MTX influx route), in that it is not inhibited by bromosulfophtalein or verapamil but is inhibited by the N-hydroxysuccinimide ester of MTX, a specific inhibitor of MTX influx, and a 10-fold higher concentration of probenecid than that required to inhibit ATP-dependent efflux. Under these conditions, MTX did not trans-stimulate [3H]MTX efflux. Also, no evidence was obtained for a putative bromosulfophthalein-insensitive, probenecid-inhibitable route for [3H]MTX efflux. In cells depleted to the extent of 90–95% of their ATP by 60-min incubation in medium in the absence of d-glucose and with 10 mm sodium azide, overall efflux of [3H]MTX was markedly reduced and appears to be mediated solely by the MTX influx route. Influx of [3H]MTX was both cis and trans inhibited by probenecid, and efflux under these conditions was markedly inhibited by the N-hydroxysuccinimide ester of MTX and trans-stimulated by MTX. Over-all, the results of these studies are consistent with a model for methotrexate transport in L1210 cells derived [Dembo et al., J. Membrane Biol., 78: 9–17, 1984] in the authors' laboratory based solely upon a kinetic analysis of [3H]MTX influx and efflux in ATP-replete and depleted L1210 cells. As such, these new results identify a single ATP-dependent efflux route as the bromosulfophthalein-, probenecid-, and verapamil-inhibitable route in L1210 cells under conditions that maintain ATP levels at maximum.

Footnotes

  • ↵1 Supported in part by Grants CA 08748 and CA 46673 from the National Cancer Institute, Grant CH-26 from the American Cancer Society, and the Elsa U. Pardee Foundation.

  • ↵2 To whom requests for reprints should be addressed, at Laboratory for Molecular Therapeutics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.

  • Received August 30, 1990.
  • Accepted December 20, 1990.
  • ©1991 American Association for Cancer Research.
PreviousNext
Back to top
March 1991
Volume 51, Issue 5
  • Table of Contents
  • Table of Contents (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Issues of Transport Multiplicity and Energetics Pertaining to Methotrexate Efflux in L1210 Cells Addressed by an Analysis of Cis and Trans Effects of Inhibitors
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Issues of Transport Multiplicity and Energetics Pertaining to Methotrexate Efflux in L1210 Cells Addressed by an Analysis of Cis and Trans Effects of Inhibitors
F. M. Sirotnak and D. F. O'Leary
Cancer Res March 1 1991 (51) (5) 1412-1417;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The Issues of Transport Multiplicity and Energetics Pertaining to Methotrexate Efflux in L1210 Cells Addressed by an Analysis of Cis and Trans Effects of Inhibitors
F. M. Sirotnak and D. F. O'Leary
Cancer Res March 1 1991 (51) (5) 1412-1417;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • The Role of Chimeric Paired Box Transcription Factors in the Pathogenesis of Pediatric Rhabdomyosarcoma
  • Laureate Citations
  • Role of TCL1 and ALL1 in Human Leukemias and Development
Show more Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement